Pleural Effusions Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Pleural Effusions Treatment Market is segmented by Disease Type (Transudative, Exudative), End User (Hospitals, Ambulatory Clinics, and Other End Users), and Geography

Market Snapshot

Pleural effusion CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pleural effusions treatment market is anticipated to record a CAGR of nearly 4.7% during the forecast period. Certain factors that are driving the market growth include increasing prevalence of pleural effusions and the noteworthy progress in managing the disease. Pleural effusion refers to the abnormal collection of fluid present in the pleural space, generally resulting from excess fluid production and/or decreased lymphatic absorption. It is the most common manifestation of pleural disease, and its etiologies range in variety, from cardiopulmonary disorders and/or systemic inflammatory conditions to malignancy. According to a 2017 report published by the McGovern Medical School at UTHealth at The University of Texas Health Science Center at Houston, approximately 1.5 million pleural effusions are diagnosed in the United States each year. Such factors are expected to drive market growth over the forecast period. Moreover, the management of pleural effusion, including the malignant one, continues to evolve with the introduction of tunneled pleural catheters and procedures that combine these along with chemical pleurodesis. Such advances in the therapeutic evaluation of pleural effusions, as well as a growing multidisciplinary interest in this field, hold significant opportunities for the market to grow over the forecast period.

Scope of the Report

Pleural effusions treatment is generally the therapy of pleural effusion, i.e. an abnormal collection of fluid between the thin layers of tissue (pleura) lining the lung and the wall of the chest cavity. The market studied is segmented on the basis of treatment type and end user.

By Disease Type
By End User
Ambulatory Clinics
Other End Users
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Transudative Pleural Effusions Segment Shows Lucrative Opportunity in the Pleural Effusions Treatment Market

  • Transudative pleural effusion fluid is similar to the fluid that one normally has in his/her pleural space. It forms from liquid leaking across normal pleura. This type rarely needs to be drained unless it is very large. Congestive heart failure is the most common cause of all pleural effusions in developed countries and accounts for the overwhelming majority of transudative pleural effusions.
  • A transudative pleural effusion develops when the systemic factors influencing the formation or absorption of the pleural fluid are altered. The pleural surfaces are not involved by the primary pathologic process. The diagnosis of transudative effusion is simple to establish by examining the characteristics of the pleural fluid.
  • Exudative pleural effusion also holds a major share of the market. Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease.
pleural effusions treatment Market.PNG

North America Dominates the Pleural Effusions Treatment Market

  • North America currently dominates the market and is expected to continue its stronghold over the forecast period. This can be primarily attributed to the increasing prevalence of respiratory diseases, and also to the rise in technological advancements as well as the availability of organized healthcare facilities.
  • According to the American Cancer Society estimates, lung cancer was the deadliest malignancy in the United States in 2018. It is the second most prevalent cancer in men and women and the commonest cause of malignant pleural effusion (MPE), accounting for approximately 30% of such effusions.
  • Most patients with pleural effusion visit a doctor complaining of shortness of breath, which is caused by fluid accumulating in the chest and compressing the lung. Once a malignant pleural effusion is diagnosed, the prognosis is very poor, with patients living only another four months on average.
pleural effusions treatment market.png

Competitive Landscape

The pleural effusions treatment market is competitive and consists of a few major players. Companies like B. Braun Melsungen, Becton, Dickinson and Company, Bicakcilar, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, and Smith Medical, among others, hold the substantial market share in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Pleural Effusions

      2. 4.2.2 Significant Progress in the Management of Pleural Effusions

    3. 4.3 Market Restraints

      1. 4.3.1 Partial Success Rate of Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Disease Type

      1. 5.1.1 Transudative

      2. 5.1.2 Exudative

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Ambulatory Clinics

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 B. Braun Melsungen

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Bicakcilar

      4. 6.1.4 Biometrix

      5. 6.1.5 Cook Medical

      6. 6.1.6 Grena

      7. 6.1.7 Redax

      8. 6.1.8 Rocket Medical

      9. 6.1.9 Smith Medical

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pleural Effusions Treatment Market market is studied from 2018 - 2026.

The Pleural Effusions Treatment Market is growing at a CAGR of 4.7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Becton, Dickinson and Company , Biometrix , Redax , Grena , B. Braun Melsungen are the major companies operating in Pleural Effusions Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!